ProCE Banner Activity

Incorporating PARP Inhibitors for mCRPC: A Nursing Perspective

Clinical Thought

PARP inhibitors are an option for patients with metastatic castration-resistant prostate cancer and certain gene mutations. Read this expert commentary to learn about the evidence supporting PARP inhibitor therapy and gain insight into strategies to manage adverse events associated with PARP inhibitors.

Released: May 31, 2022

Expiration: May 30, 2023

Begin Activity

Share

Faculty

Brenda Martone

Brenda Martone, MSN, ANP-BC, AOCNP

Nurse Practitioner
Genitourinary Oncology
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois

Acknowledgement

This activity is supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme Corp.

Target Audience

NPs and PAs in oncology

Disclosure

Brenda Martone, MSN, ANP-BC, AOCNP has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.